Merit Medical Systems

Merit Medical Systems, Inc. engages in the manufacture and marketing of proprietary disposable medical devices. It operates through the Cardiovascular and Endoscopy segments. The Cardiovascular segment consists of peripheral intervention, cardiac intervention, interventional oncology and spine, and cardiovascular and critical care product groups. The Endoscopy segment integrates non-vascular stent technology with balloon dilators, inflation devices, guide wires, procedure kits, and other devices that are used by gastroenterologists, endoscopists, pulmonologists, and thoracic and general surgeons. The company was founded by Fred P. Lampropoulos, Darla Gill, Kent W. Stanger, and William Padilla in July 1987 and is headquartered in South Jordan, UT.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Merit Medical Systems reports robust Q4 performance and eyes growth

Merit Medical Systems delivered a strong Q4 performance with revenue growth, increased gross profit, and exceeding net income expectations.
While facing challenges in certain segments and regulatory compliance, the company remains optimistic about growth opportunities and operational improvements.
Strategic pricing initiatives and a focus on achieving financial targets position Merit Medical for continued success and potential expansion through M&A activities.
The company's commitment to discipline, prioritization, and operational excellence underscores its resilience and potential for sustained growth in the future.

Merit Medical Systems posts strong Q1 results, eyes debt reduction

Merit Medical Systems delivered robust financial results in Q1 2023, showcasing growth in revenue, operating income, and net income. The company maintains its financial guidance for 2023, emphasizing a commitment to debt reduction and free cash flow targets. Analyst inquiries highlighted areas for improvement and strategic focus moving forward.

Merit Medical Systems reports robust Q2 earnings amidst strategic acquisitions

Merit Medical Systems delivered strong financial performance in Q2 2023, marked by revenue growth, improved profitability, and strategic acquisitions. While facing challenges in the Endoscopy segment and uncertainties in international markets, the company remains focused on leveraging opportunities in catch-up procedures and strategic M&A for sustainable growth.

Merit Medical Systems excels in Q3, eyes growth opportunities

Merit Medical Systems delivered a strong Q3 performance with notable revenue growth, profit increases, and enhanced net income and EPS.
While facing challenges like margin pressure and regional headwinds, the company remains focused on long-term growth strategies and operational efficiency.
With opportunities for revenue expansion, product advancements, and margin improvements on the horizon, Merit Medical Systems is poised for continued success and shareholder value creation.

Merit Medical Systems excels in Q4 2023, eyes strategic growth

Merit Medical Systems delivered strong financial results in Q4 2023, driven by revenue growth and margin expansion.
The company's strategic initiatives and focus on operational efficiency position it well for future growth and profitability.
Challenges such as SKU rationalization and China revenue decline require careful management and strategic planning.
Opportunities in M&A, pricing power initiatives, R&D investments, and gross margin expansion strategies offer avenues for continued success.

Merit Medical Systems excels in Q1, eyes growth opportunities

Merit Medical Systems delivered strong Q1 results with revenue growth and profitability improvements, driven by operational progress and strategic focus on innovation.
While facing challenges such as pricing pressures in China and debt reduction strategies, the company remains poised for growth through new opportunities and market strategies.
With a solid performance in Q1 and positive Q2 guidance, Merit Medical Systems demonstrates resilience and a strategic approach to navigating industry challenges.
The company's commitment to financial stability, innovation, and shareholder value sets a strong foundation for future growth and market competitiveness.

Merit Medical Systems reports robust Q3 results amidst supply challenges

Merit Medical Systems delivered strong financial results in Q3, driven by revenue growth and margin improvement.
The company's strategic acquisition and focus on innovation position it well for future growth despite supply chain disruptions.
Challenges in supply chain management and analyst inquiries highlight areas for ongoing attention and improvement.
Overall, Merit Medical Systems maintains a positive outlook on its performance and growth trajectory.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

*  Core revenue on a constant currency basis, non-GAAP EPS, non-GAAP net income, non-GAAP operating margin, non-GAAP gross margin and free cash flow are non-GAAP financial measures. A reconciliation of these and other non-GAAP financial measures used in this release to their most directly comparable GAAP financial measures is included under the heading “Non-GAAP Financial Measures” below.

Merit Medical Reports Results for Third Quarter; Issues Updated 2020 Guidance

Merit Medical (MMSI) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Analysts Estimate Merit Medical (MMSI) to Report a Decline in Earnings: What to Look Out for

SOUTH JORDAN, Utah, Oct. 13, 2020 (GLOBE NEWSWIRE) -- Merit Medical Systems, Inc. (NASDAQ: MMSI), a leading manufacturer and marketer of proprietary disposable devices used in interventional, diagnostic and therapeutic procedures, particularly in cardiology, radiology, oncology, critical care and endoscopy, announced today that it has finalized its settlement with the U.S. Department of Justice and the U.S. Department of Health and Human Services. In order to avoid distraction from its core mission, and the cost of litigating the matter to success, Merit agreed to pay $18 million to the federal government and certain states. The settlement agreement does not constitute a finding of wrongdoing by Merit or its management, and it expressly recognizes that Merit denies the allegations.

Merit Medical Systems Finalizes Resolution with the Government

“Foundations for Growth” Investor Call will Introduce the Company’s Multi-Year Financial Targets for Growth and Improved Profitability “Foundations for Growth” Investor Call will Introduce the Company’s Multi-Year Financial Targets for Growth and Improved Profitability

Merit Medical Systems to Announce Third Quarter Results on October 28, 2020 and Host “Foundations for Growth” Investor Call on November 10, 2020

DaVita

OPKO Health

Backed by projections of robust earnings growth rates,  there are a few MedTech stocks which are ideal for long-term bet.

3 Great MedTech Stocks to Pick Amid the Coronavirus Crisis

GALWAY, Ireland--(BUSINESS WIRE)-- #cambusmedical--The acquired assets will be absorbed by Cambus Medical, a Freudenberg Medical company and market leading hypotube manufacturer.

Freudenberg Medical Acquires the Merit Medical Hypotube Manufacturing Business

SOUTH JORDAN, Utah, Sept.  02, 2020  (GLOBE NEWSWIRE) -- Merit Medical Systems, Inc. (NASDAQ: MMSI), a leading manufacturer and marketer of proprietary disposable devices used in interventional, diagnostic and therapeutic procedures, particularly in cardiology, radiology, oncology, critical care and endoscopy, announced today that it will participate at four conferences in September.

Merit Medical to Participate at Four Conferences in September

Merit Medical (MMSI) reported earnings 30 days ago. What's next for the stock?

Why Is Merit Medical (MMSI) Up 7.1% Since Last Earnings Report?

QIAGEN

MedTech stocks play a major role in holding the index up and ending the shortest bear run in the history of S&P 500.

MedTech Lifts S&P 500 Index: 3 Stocks With Upside Potential

Merit Medical Systems, Inc. (MMSI) CEO Fred Lampropoulos on Q2 2020 Results - Earnings Call Transcript

Merit Medical (MMSI) delivered earnings and revenue surprises of 933.33% and 13.01%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?

Merit Medical (MMSI) Tops Q2 Earnings and Revenue Estimates

* Core revenue on a constant currency basis, non-GAAP EPS, non-GAAP net income, non-GAAP operating margin, non-GAAP gross margin and free cash flow are non-GAAP financial measures. A reconciliation of these and other non-GAAP financial measures used in this release to their most directly comparable GAAP financial measures is included under the heading “Non-GAAP Financial Measures” below.

Merit Medical Reports Results for Quarter Ended June 30, 2020

Merit Medical Systems shows improving price performance, earning an upgrade to its IBD Relative Strength Rating from 77 to 81.
The post Merit Medical Systems Scores Relative Strength Rating Upgrade; Hits Key Benchmark appeared first on Investor's Business Daily.

Merit Medical Systems Scores Relative Strength Rating Upgrade; Hits Key Benchmark

Merit Medical Systems (MMSI) had its Relative Strength (RS) Rating upgraded from 70 to 77 Monday -- a welcome improvement, but still below the 80 or higher score you prefer to see.

Merit Medical Systems Trying To Close In On Key Technical Benchmark

Earnings Preview: Merit Medical (MMSI) Q2 Earnings Expected to Decline

SOUTH JORDAN, Utah, July  17, 2020  (GLOBE NEWSWIRE) -- Merit Medical Systems, Inc. (NASDAQ: MMSI), a leading manufacturer and marketer of proprietary disposable devices used primarily in cardiology, radiology, oncology, critical care and endoscopy announced today that it will release its financial results for the quarter ended June 30, 2020, after the close of the stock market on Wednesday, July 29, 2020.

Merit Medical Systems to Announce Second Quarter Results on July 29, 2020

Merit Medical (MMSI) saw a big move last session, as its shares jumped more than 6% on the day, amid huge volumes.

Merit Medical (MMSI) Looks Good: Stock Adds 6.7% in Session

SOUTH JORDAN, Utah, July  15, 2020  (GLOBE NEWSWIRE) -- Merit Medical Systems, Inc. (NASDAQ: MMSI), a leading manufacturer and marketer of proprietary disposable devices used in interventional, diagnostic and therapeutic procedures, particularly in cardiology, radiology, oncology, critical care and endoscopy, today announced that it has reached an agreement in principle with the Department of Justice (“DOJ”) to fully resolve the DOJ’s investigation of certain marketing and promotional practices, which has been previously disclosed. Merit currently expects to pay $18 million in connection with the resolution; however, Merit denies the allegations.

Merit Medical Announces Agreement in Principle with Department of Justice

Investor confidence is high on Merit Medical (MMSI) stock, thanks to solid prospects.

Here's Why You Should Retain Merit Medical (MMSI) for Now

PHILADELPHIA, June 6, 2020 /PRNewswire/ -- Kaskela Law LLC announces that it is investigating Merit Medical Systems, Inc. ("Merit Medical" or the "Company") (Nasdaq: MMSI) on behalf of the Company's stockholders. Recently a shareholder class action complaint was filed in federal court on...

Kaskela Law LLC Announces Investigation of Merit Medical Systems, Inc. (MMSI) and Encourages Long-Term MMSI Investors to Contact the Firm

Starboard Value, a top-tier activist investor firm, amassed a 9% stake in Merit Medical Systems, Inc. (NASDAQ: MMSI), a manufacturer of disposable medical devices, CNBC reported.

Activist Starboard Value targets medical device company

A successful activist is gently pushing for change at Merit Medical Systems.

Activist Starboard pushes for change at a medical device company that could be a takeover candidate

Nominates Three Medical Device Industry Veterans – Lonny Carpenter, David Floyd    and James Hogan – for Election to the Board of Directors

Merit Medical Announces Agreement With Starboard

SOUTH JORDAN, Utah, May  26, 2020  (GLOBE NEWSWIRE) -- Merit Medical Systems, Inc. (NASDAQ: MMSI), a leading manufacturer and marketer of proprietary disposable devices used in interventional, diagnostic and therapeutic procedures, particularly in cardiology, radiology, oncology, critical care and endoscopy, today announced that it received the CE mark for the WRAPSODY™ Endovascular Stent Graft System from the British Standards Institution (BSI). The WRAPSODY system is a flexible self-expanding endoprosthesis indicated for use in hemodialysis patients for the treatment of stenosis or occlusion within central veins as well as the dialysis outflow circuit of an arteriovenous (AV) fistula or AV graft.

News for Merit Medical Systems Stock (MMSI)